NeOnc Technologies (NTHI) Posts 48.9% Six-Month PFS in Phase 2a Brain Cancer Study — Stock Up 19% Pre-Market

NeOnc Technologies (Nasdaq: NTHI) released its Phase 2a topline readout on August 12. The six-month progression-free survival rate was 48.9% (95% CI: 26.3–68.1). The pre-specified standard-of-care benchmark in the study design was 20%. The p-value was 0.0047. The study met its primary endpoint.

The data come from NEO100-01, an open-label trial of intranasal NEO100™ — a purified perillyl alcohol formulation — in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. Per NeOnc's August 12 announcement, 24 patients enrolled at the recommended Phase 2 dose of 1,152 mg/day, self-administered intranasally four times daily in 28-day cycles until progression, death, or withdrawal. The PFS-6 figure was measured by RANO 2.0 criteria using Kaplan-Meier estimation, per the company's SEC Form 8-K filing.

Secondary survival endpoints filled out the picture. Median overall survival came in at 26.09 months across the 24-patient cohort, with 12 deaths recorded. Overall survival was 86.7% at six months, 60.9% at twelve months, and 54.1% at twenty-four months, per the same filing.

The disease setting: per the company's August 12 announcement, there is no approved targeted therapy for recurrent IDH1-mutant high-grade glioma — patients who have already progressed after radiation and temozolomide. The 20% PFS-6 figure was pre-specified in the study design as the expectation for standard of care in that population.

Market reaction was immediate. In pre-market trading on August 12, NTHI was at $5.24, up 19.08% on the Nasdaq, per RTT News reported 44 minutes before market open. The stock's August 10 closing price was $3.50 against a 52-week range of $3.01–$12.95, per Morningstar. Shares outstanding stand at 25.94 million, with a market cap of $90.76 million as of August 10, 2026, also per Morningstar.

A GlobeNewswire report from August 11, 2026 noted NTHI was heading into Wednesday with more than 500,000 shares reported short and three Wall Street Buy ratings.

Executive Chairman, President and CEO Amir Heshmatpour framed the moment in NeOnc's August 10 Q2 earnings release: "We completed the topline analysis of our fully enrolled Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma and look forward to presenting the results to investors on August 12. This is one of the most important clinical milestones in NeOnc's history."

The company's stated next step is a Type B meeting request with the U.S. Food and Drug Administration to align on a registrational development path for NEO100 in recurrent IDH1-mutant high-grade glioma, per the August 12 announcement.

NeOnc's broader NEO™ platform carries patent protections extending to 2038, per company disclosures.